CN108794510B - A double-radical compound composed of triarylmethyl radical and nitroxide radical and salt thereof, preparation method and application thereof - Google Patents
A double-radical compound composed of triarylmethyl radical and nitroxide radical and salt thereof, preparation method and application thereof Download PDFInfo
- Publication number
- CN108794510B CN108794510B CN201810824031.7A CN201810824031A CN108794510B CN 108794510 B CN108794510 B CN 108794510B CN 201810824031 A CN201810824031 A CN 201810824031A CN 108794510 B CN108794510 B CN 108794510B
- Authority
- CN
- China
- Prior art keywords
- compound
- salt
- radical
- diradical
- dnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 88
- -1 triarylmethyl radical Chemical class 0.000 claims abstract description 58
- 238000006482 condensation reaction Methods 0.000 claims abstract description 10
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims abstract description 4
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- AKRYBBWYDSDZHG-UHFFFAOYSA-N nitrosobis(2-oxopropyl)amine Chemical compound CC(=O)CN(N=O)CC(C)=O AKRYBBWYDSDZHG-UHFFFAOYSA-N 0.000 claims description 9
- 239000007821 HATU Substances 0.000 claims description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 239000012317 TBTU Substances 0.000 claims description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 9
- 230000003993 interaction Effects 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 230000028161 membrane depolarization Effects 0.000 abstract description 5
- 238000012986 modification Methods 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 229940125904 compound 1 Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 11
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940126214 compound 3 Drugs 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 9
- 238000004896 high resolution mass spectrometry Methods 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- 230000010287 polarization Effects 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 238000011056 performance test Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- JWUXJYZVKZKLTJ-UHFFFAOYSA-N Triacetonamine Chemical compound CC1(C)CC(=O)CC(C)(C)N1 JWUXJYZVKZKLTJ-UHFFFAOYSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BXBJZYXQHHPVGO-UHFFFAOYSA-N 4-hydroxycyclohexan-1-one Chemical compound OC1CCC(=O)CC1 BXBJZYXQHHPVGO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- GHJUORCGZFHNKG-UHFFFAOYSA-N 1,2,2,6,6-pentamethylpiperidin-4-one Chemical compound CN1C(C)(C)CC(=O)CC1(C)C GHJUORCGZFHNKG-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- MQSRKJKAOOSCFF-UHFFFAOYSA-N [N].[N].[O] Chemical compound [N].[N].[O] MQSRKJKAOOSCFF-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- YLFIGGHWWPSIEG-UHFFFAOYSA-N aminoxyl Chemical compound [O]N YLFIGGHWWPSIEG-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/30—Assessment of water resources
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本发明提供一种由三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐、其制备方法和应用,双自由基化合物结构式由下述式1表示:制备方法包括:化合物A1与化合物A2发生酸胺缩合反应,得到化合物A3;化合物A3与化合物A4发生酸胺缩合反应,得到双自由基化合物及其盐。该双自由基极化剂同时具有氮氧自由基和三芳基甲基自由基部分具有如下优势:频率匹配性更优,CE效率更高;在魔角旋转的条件下不存在去极化效应,高场DNP增强效果更优;具有的较强的交换相互作用;具有良好的水溶性,因此DNP增强倍数高;对R1、R2、R3、R4、R5、R6基团的修饰可适度提高交换相互作用、提高双自由基的弛豫时间和双自由基的水溶性,从而提高极化剂的DNP性质。The present invention provides a biradical compound composed of triarylmethyl radical and nitroxide radical and salt thereof, a preparation method and application thereof, and the structural formula of the biradical compound is represented by the following formula 1: The preparation method includes: compound A1 and compound A2 undergo acid-amine condensation reaction to obtain compound A3; compound A3 undergoes acid-amine condensation reaction with compound A4 to obtain diradical compounds and salts thereof. The biradical polarizer has both nitroxide radicals and triarylmethyl radical moieties, and has the following advantages: better frequency matching, higher CE efficiency; no depolarization effect under the condition of magic angle rotation, High-field DNP enhancement effect is better; has strong exchange interaction; has good water solubility, so DNP enhancement ratio is high; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 groups Modification can moderately improve the exchange interaction, the relaxation time of diradicals and the water solubility of diradicals, thereby improving the DNP properties of polarizers.
Description
技术领域technical field
本发明涉及核磁共振技术领域,尤其是涉及一种由三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐、其制备方法和应用。The invention relates to the technical field of nuclear magnetic resonance, in particular to a diradical compound composed of a triarylmethyl radical and a nitroxide radical and a salt thereof, a preparation method and application thereof.
背景技术Background technique
核磁共振技术是用于物质化学结构表征的重要手段,广泛应用于化学,材料学,生物化学等领域,尤其是固态核磁共振技术使得生物大分子如蛋白质分子的结构解析成为可能,但其应用受限于固有低灵敏度。针对这一缺陷,目前有两方面的努力,一方面是提高仪器的磁场强度,进而提高热平衡下核的极化率,但该方法的费用昂贵,技术要求高;另一方面是通过动态核极化(DNP)技术使核的极化效率提高,从而增强信号强度,提高灵敏度。极化剂的选用是动态核极化实验的关键,直接决定了DNP的信号增强倍数。现有极化试剂的DNP增强倍数远远低于理论值(1H,658倍;13C,2600倍)。Nuclear magnetic resonance technology is an important means for the characterization of chemical structures of substances, and is widely used in chemistry, materials science, biochemistry and other fields, especially solid-state nuclear magnetic resonance technology makes it possible to analyze the structure of biological macromolecules such as protein molecules, but its application is limited. Limited to inherently low sensitivity. Aiming at this defect, there are currently two efforts. On the one hand, it is to improve the magnetic field strength of the instrument, thereby increasing the polarizability of the nucleus under thermal equilibrium, but this method is expensive and requires high technical requirements; The polarization efficiency of the nucleus is enhanced by the DNP (DNP) technology, thereby enhancing the signal strength and improving the sensitivity. The choice of polarizer is the key to the dynamic nuclear polarization experiment, which directly determines the signal enhancement factor of DNP. The DNP enhancement factor of the existing polarizing agents is much lower than the theoretical value ( 1 H, 658-fold; 13 C, 2600-fold).
自从60年前DNP技术首次被提出,所有的实验都依赖于单自旋中心,例如用氮氧自由基TEMPO和金属原子作为极化来源。目前对于DNP技术而言,最有效的机制为CE(crosseffect)机制,而CE机制与电子间的偶极相互作用与自旋相互作用密切相关。2003年,Kan-Nian Hu和Robert G.Griffin首次提出双氮氧自由基的概念,将两个TEMPO用PEG链连接,使得偶极相互作用增强,相对于单氮氧自由基信号强度提高4倍。从此,双氮氧自由基开始作为DNP极化剂受到关注。然而,氮氧自由基仍存在稳定性不好,水溶性较差,单峰线宽仍较宽,弛豫时间不长和交换相互作用较弱的问题,并且双氮氧自由基在魔角旋转的条件下存在核的去极化效应,这使双氮氧自由基DNP效率减弱,高场DNP增强效果不佳,限制了动态核极化技术的发展,使固态核磁共振灵敏度的提高受限。Since the DNP technique was first proposed 60 years ago, all experiments have relied on single spin centers, such as nitroxide radicals TEMPO and metal atoms as polarization sources. Currently, for DNP technology, the most effective mechanism is CE (crosseffect) mechanism, and CE mechanism is closely related to the dipole interaction and spin interaction between electrons. In 2003, Kan-Nian Hu and Robert G. Griffin first proposed the concept of nitroxide radicals, linking two TEMPOs with PEG chains, which enhanced the dipole interaction and increased the signal intensity by 4 times compared to single nitroxide radicals. . Since then, nitroxide radicals have been attracting attention as DNP polarizers. However, nitroxide still has problems of poor stability, poor water solubility, wide single peak linewidth, short relaxation time and weak exchange interaction, and the nitroxide rotates at the magic angle. There is a nuclear depolarization effect under the condition of , which weakens the efficiency of nitroxide radical DNP, and the enhancement effect of high-field DNP is not good, which limits the development of dynamic nuclear polarization technology and the improvement of solid-state NMR sensitivity.
根据氮氧双自由基用作DNP极化剂的相关研究,证实电子弛豫时间、交换相互作用、水溶性等因素均会影响极化剂的DNP性质。对于双氮氧自由基而言,通过延长弛豫时间可有效提高DNP增强倍数,相关研究表明,对于氮氧双自由基而言,弛豫时间已达到最优化条件,已没有可提升的空间。研究证实交换相互作用与极化剂的高场DNP性质有密切联系,TN双自由基具有明显强于氮氧双自由基的交换相互作用,使得其在高场没有核的去极化效应(氮氧双自由基去极化效应明显),这也是其高场DNP性质优于氮氧双自由基的重要因素,故适度增强交换相互作用也是TN双自由基极化剂设计的一个重要考虑因素。在低温下,极化剂存在自聚集现象,使得极化转移损失,转移效率降低,故提高水溶性,增强极化剂在溶液中的分散度,也是优化极化剂的一个有效方法。According to the relevant research on the use of nitroxide as a polarizer for DNP, it is confirmed that factors such as electron relaxation time, exchange interaction, and water solubility can affect the DNP properties of polarizers. For nitroxide radicals, the enhancement factor of DNP can be effectively increased by prolonging the relaxation time. Relevant studies have shown that for nitroxide radicals, the relaxation time has reached the optimal conditions, and there is no room for improvement. Studies have confirmed that the exchange interaction is closely related to the high-field DNP properties of polarizers. The depolarization effect of oxygen biradical is obvious), which is also an important factor for its high-field DNP properties to be superior to nitroxide biradicals. Therefore, moderately enhancing the exchange interaction is also an important consideration in the design of TN biradical polarizers. At low temperature, the polarizer has a self-aggregation phenomenon, which makes the polarization transfer loss and the transfer efficiency decrease. Therefore, improving the water solubility and enhancing the dispersion of the polarizer in the solution is also an effective method to optimize the polarizer.
发明内容SUMMARY OF THE INVENTION
本发明要解决的问题是提供一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐、其制备方法和应用,该类化合物稳定性好,水溶性佳,其DNP增强倍数高,可有效增强固态核磁共振的灵敏度。The problem to be solved by the present invention is to provide a di-radical compound composed of triarylmethyl radical and nitroxide radical and its salt, its preparation method and application. The enhancement multiple is high, which can effectively enhance the sensitivity of solid-state NMR.
为解决上述技术问题,本发明的一个目的是提供一种由三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,其结构式由下述式1表示:In order to solve the above-mentioned technical problems, an object of the present invention is to provide a kind of two-radical compound and salt thereof composed of triarylmethyl radical and nitroxide radical, and its structural formula is represented by following formula 1:
其中,in,
R1选自H或C1-C18饱和烷基中的一种,C1-C18饱和烷基表示含有1-18个碳原子的直链或支链烷基,例如甲基、乙基、丙基、丁基、异丙基等,优选的,R1为H或CH3;R 1 is selected from one of H or C1-C18 saturated alkyl group, C1-C18 saturated alkyl group represents a straight or branched chain alkyl group containing 1-18 carbon atoms, such as methyl, ethyl, propyl, Butyl, isopropyl, etc., preferably, R 1 is H or CH 3 ;
R2选自H、C1-C6饱和烷基和天然氨基酸或非天然氨基酸的相应侧链取代基中的一种,C1-C6饱和烷基表示含有1-6个碳原子的直链或支链烷基,例如甲基、乙基、丙基、丁基、异丙基等,天然氨基酸或非天然氨基酸的相应侧链取代基指:氨基酸通式中,不同的氨基酸侧链R取代基不同,式1中R2与R对应,R2选自天然或非天然氨基酸中的侧链R取代基,优选的,R2为H、CH3或天然氨基酸或非天然氨基酸的相应侧链取代基中的一种;R 2 is selected from one of H, C1-C6 saturated alkyl and corresponding side chain substituents of natural amino acids or unnatural amino acids, C1-C6 saturated alkyl represents a straight or branched chain containing 1-6 carbon atoms Alkyl, such as methyl, ethyl, propyl, butyl, isopropyl, etc., the corresponding side chain substituents of natural amino acids or unnatural amino acids refer to: amino acid general formula In, different amino acid side chain R substituents are different, in formula 1 R 2 corresponds to R, R 2 is selected from the side chain R substituents in natural or unnatural amino acids, preferably, R 2 is H, CH 3 or natural one of the corresponding side chain substituents of an amino acid or an unnatural amino acid;
R3选自H、C1-C18饱和烷基或(CH2CH2O)nH中的一种,1≤n≤20,C1-C18饱和烷基表示含有1-18个碳原子的直链或支链烷基,例如甲基、乙基、丙基、丁基、异丙基等,优选的,R3为H或(CH2CH2O)nH中的一种,1≤n≤20,更优选的,R3为H或(CH2CH2O)2H;R 3 is selected from one of H, C1-C18 saturated alkyl or (CH 2 CH 2 O) n H, 1≤n≤20, C1-C18 saturated alkyl represents a straight chain containing 1-18 carbon atoms Or branched alkyl, such as methyl, ethyl, propyl, butyl, isopropyl, etc., preferably, R 3 is one of H or (CH 2 CH 2 O) n H, 1≤n≤ 20, more preferably, R 3 is H or (CH 2 CH 2 O) 2 H;
R4、R5相同或不同的选自烷基或R4与R5相连形成X为O、S、CHOH、NCH3或NH,m=0、1或2,优选的,R4、R5为CH3或R4与R5相连形成 The same or different R 4 and R 5 are selected from alkyl or R 4 is connected with R 5 to form X is O, S, CHOH, NCH 3 or NH, m=0, 1 or 2, preferably, R 4 and R 5 are CH 3 or R 4 is connected with R 5 to form
R6为CH3、CD3、CH2CH2OH或同碳上的两个R6相连形成环状结构,优选的,R6为CH3、CD3或同碳上的两个R6相连为环状结构。R 6 is CH 3 , CD 3 , CH 2 CH 2 OH or connected with two R 6 on carbon to form a ring structure, preferably, R 6 is CH 3 , CD 3 or connected with two R 6 on carbon is a ring structure.
该化合物通过连接链将氮氧自由基与三芳基甲基自由基(trityl)相连,形成了同时具有氮氧自由基和三芳基甲基自由基的双自由基极化剂。氮氧自由基-三芳基甲基自由基型双自由基相比双氮氧自由基主要有以下几方面的优势:首先,对于高场DNP而言,CE(cross effect)机制为最有效的机制,当电子自旋频率之差与核的拉曼频率相匹配时,CE机制可实现效率最大化,而氮氧自由基-三芳基甲基自由基型双自由基的频率匹配性优于双氮氧自由基,故其CE效率更高。其次,双氮氧自由基在魔角旋转的条件下存在核的去极化效应,这使其DNP效率减弱,但对于该氮氧自由基-三芳基甲基自由基型双自由基并没有去极化效应,这使其高场DNP增强效果优于双氮氧自由基。另外,实验结果提示,氮氧自由基-三芳基甲基自由基型双自由基与氮氧双自由基比较,其所具有的较强的交换相互作用明显区别于氮氧双自由基,并且之前有文献报道,对于高场DNP,偶极相互作用的影响非常小,起主导作用的是交换相互作用,因此,较强的交换相互作用也使该化合物具有相比于氮氧双自由基化合物更高的高场DNP增强倍数。但交换相互作用也不是越强越好,只有当交换相互作用恰到好处时,才能使DNP效率最大化。最后,三芳基甲基自由基具有良好的水溶性,且可修饰位点丰富,可用于不同用途的功能衍生化。The compound connects nitroxide radicals with trityl radicals through a linking chain, forming a biradical polarizer with both nitroxide radicals and triarylmethyl radicals. Nitroxyl radical-triarylmethyl radical type diradical has the following advantages over dinitroxide radical: First, for high-field DNP, the CE (cross effect) mechanism is the most effective mechanism , when the difference in electron spin frequency matches the Raman frequency of the nucleus, the CE mechanism can achieve maximum efficiency, while the frequency matching of nitroxide-triarylmethyl-type bis-radical is better than that of bis-nitrogen Oxygen free radicals, so its CE efficiency is higher. Secondly, under the condition of magic angle rotation, the bis-nitroxide radical has the depolarization effect of the nucleus, which weakens the DNP efficiency, but the nitroxyl radical-triarylmethyl radical type double radical does not depolarize the nitroxide radical. polarization effect, which makes the high-field DNP enhancement effect better than that of nitroxide radicals. In addition, the experimental results suggest that the nitroxide radical-triarylmethyl radical type diradical has a stronger exchange interaction than nitroxide radicals, which is significantly different from that of nitroxide radicals. It has been reported in the literature that for high-field DNP, the effect of dipole interaction is very small, and the dominant role is exchange interaction. Therefore, the stronger exchange interaction also makes this compound more efficient than nitroxide biradical compounds. High high-field DNP enhancement factor. But the exchange interaction is not as strong as possible. Only when the exchange interaction is just right can the DNP efficiency be maximized. Finally, the triarylmethyl radical has good water solubility and abundant modifiable sites, which can be used for functional derivatization for different purposes.
技术方案中,优选的,R1、R2和R3不同时为氢或R4、R5和R6不同时为甲基,优选的,R1、R2和R3不同时为氢。根据氮氧双自由基用作DNP极化剂的相关研究,证实电子弛豫时间、交换相互作用、水溶性等因素均会影响极化剂的DNP性质,结合双自由基的弛豫时间、交换相互作用以及水溶性,1)R1、R2和R3基团的修饰可适度提高交换相互作用;2)R4、R5、R6基团的修饰可提高双自由基的弛豫时间,其中R4与R5相连形成时可延长氮氧自由基部分的弛豫时间,R6为CD3时可提高三芳基甲基自由基部分的弛豫时间;3)R2、R3、R4、R5、R6的修饰可提高双自由基的水溶性。R2为谷氨酸、天冬氨酸、丝氨酸、苏氨酸相应的中的取代基;R3为(CH2CH2O)nH(1≤n≤20);R4与R5相连形成其中X为O、S、CHOH、NCH3或NH;或者R6为CH2CH2OH时可提高双自由基的水溶性。In the technical solution, preferably, R 1 , R 2 and R 3 are not simultaneously hydrogen or R 4 , R 5 and R 6 are not simultaneously methyl, preferably, R 1 , R 2 and R 3 are not simultaneously hydrogen. According to the related research on the use of nitroxide biradicals as DNP polarizers, it is confirmed that electron relaxation time, exchange interaction, water solubility and other factors will affect the DNP properties of polarizers. Interaction and water solubility, 1) the modification of R 1 , R 2 and R 3 groups can moderately improve the exchange interaction; 2) the modification of R 4 , R 5 , R 6 groups can improve the relaxation time of diradicals , in which R 4 is connected with R 5 to form When R 6 is CD 3 , the relaxation time of the triarylmethyl radical part can be prolonged; 3) R 2 , R 3 , R 4 , R 5 , R 6 Modification can improve the water solubility of diradicals. R 2 is the corresponding substituent in glutamic acid, aspartic acid, serine and threonine; R 3 is (CH 2 CH 2 O) n H (1≤n≤20); R 4 is connected to R 5 form Wherein X is O, S, CHOH, NCH 3 or NH; or when R 6 is CH 2 CH 2 OH, the water solubility of the diradical can be improved.
技术方案中,优选的,天然氨基酸为甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸、脯氨酸、苯丙氨酸、酪氨酸、色氨酸、丝氨酸、苏氨酸、天冬酰胺、谷氨酰胺、半胱氨酸、赖氨酸、精氨酸、组氨酸、天冬氨酸或谷氨酸,非天然氨基酸为肌氨酸或叔亮氨酸。In the technical scheme, preferably, the natural amino acids are glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan , serine, threonine, asparagine, glutamine, cysteine, lysine, arginine, histidine, aspartic acid or glutamic acid, unnatural amino acids are sarcosine or tertiary Leucine.
技术方案中,优选的,环状结构为取代或未取代的四元环、五元环或六元环,优选的,所述环状结构为环丁烷、环戊烷、环己烷、四氢呋喃、四氢吡喃、硫代环戊烷、环丁醇、环戊醇或环己醇,更优选的,所述环状结构为四氢吡喃或环己醇。In the technical scheme, preferably, the ring structure is a substituted or unsubstituted four-membered ring, five-membered ring or six-membered ring, preferably, the ring structure is cyclobutane, cyclopentane, cyclohexane, tetrahydrofuran , tetrahydropyran, thiocyclopentane, cyclobutanol, cyclopentanol or cyclohexanol, more preferably, the cyclic structure is tetrahydropyran or cyclohexanol.
技术方案中,优选的,由下式2-10之一表示:In the technical scheme, preferably, it is represented by one of the following formulas 2-10:
技术方案中,优选的,由下式3-7之一表示:In the technical scheme, preferably, it is represented by one of the following formulas 3-7:
本发明的另一目的是提供一种制备上述的双自由基化合物及其盐的方法,包括:Another object of the present invention is to provide a method for preparing the above-mentioned diradical compound and salt thereof, comprising:
第一步、使具有式A1结构的化合物与具有式A2结构的化合物发生酸胺缩合反应得到具有式A3结构的化合物;The first step is to make the compound with the structure of formula A1 and the compound with the structure of formula A2 to undergo acid amine condensation reaction to obtain the compound with the structure of formula A3;
第二步、使具有式A3结构的化合物与具有式A4结构的化合物发生酸胺缩合反应得到双自由基化合物及其盐The second step is to make the compound with the structure of formula A3 and the compound with the structure of formula A4 to undergo acid-amine condensation reaction to obtain the biradical compound and its salt
技术方案中,优选的,所述第一步中包括将化合物A1与A2溶于第一溶剂中,加入第一缩合剂和第一催化剂进行酸胺缩合反应,所述第一溶剂为二氯甲烷、乙酸乙酯、苯、甲苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲亚砜、四氢呋喃和乙醚中的一种或几种的混合,所述第一缩合剂为DCC(二环己基碳二亚胺)、EDCI(1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)、BOP(苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐)、TBTU(O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯)、HBTU(苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐)、DIC(N,N-二异丙基碳二亚胺)和HATU(2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯)中的一种或几种的组合,所述第一催化剂为HOBt(1-羟基苯并三唑)、DMAP(4-二甲氨基吡啶)和DIPEA(N,N-二异丙基乙胺)中的一种或几种的组合;In the technical scheme, preferably, the first step includes dissolving the compounds A1 and A2 in a first solvent, adding a first condensing agent and a first catalyst for acid-amine condensation reaction, and the first solvent is dichloromethane , a mixture of one or more of ethyl acetate, benzene, toluene, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, tetrahydrofuran and ether, the first A condensing agent is DCC (dicyclohexylcarbodiimide), EDCI (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), BOP (benzotriazole- 1-yloxytris(dimethylamino)phosphonium hexafluorophosphate), TBTU (O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroborate) , HBTU (benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate), DIC (N,N-diisopropylcarbodiimide) and HATU (2-( One or more combinations in 7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate), the first catalyst is HOBt (1- One or more combinations of hydroxybenzotriazole), DMAP (4-dimethylaminopyridine) and DIPEA (N,N-diisopropylethylamine);
优选的,所述第一溶剂为N,N-二甲基乙酰胺,四氢呋喃和二氯甲烷中的一种或几种的混合;Preferably, the first solvent is a mixture of one or more of N,N-dimethylacetamide, tetrahydrofuran and dichloromethane;
优选的,所述第一缩合剂为EDCI、HATU和BOP中的一种或几种的组合;Preferably, the first condensing agent is one or more combinations of EDCI, HATU and BOP;
优选的,所述第一催化剂为HOBt。Preferably, the first catalyst is HOBt.
技术方案中,优选的,第二步中包括将化合物A3与A4溶于第二溶剂中,加入第二缩合剂和第二催化剂进行酸胺缩合反应,所述第二溶剂为二氯甲烷、乙酸乙酯、苯、甲苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲亚砜、四氢呋喃和乙醚中的一种或几种的混合,所述第二缩合剂为DCC、EDCI、BOP、TBTU、HBTU、DIC和HATU中的一种或多种的组合,所述第二催化剂为HOBt、DMAP和DIPEA中的一种或几种的组合;In the technical scheme, preferably, the second step includes dissolving compounds A3 and A4 in a second solvent, adding a second condensing agent and a second catalyst for acid-amine condensation reaction, and the second solvent is dichloromethane, acetic acid A mixture of one or more of ethyl ester, benzene, toluene, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, tetrahydrofuran and diethyl ether, the second condensation The mixture is a combination of one or more of DCC, EDCI, BOP, TBTU, HBTU, DIC and HATU, and the second catalyst is a combination of one or more of HOBt, DMAP and DIPEA;
优选的,所述第二溶剂为二氯甲烷、N,N-二甲基甲酰胺和乙酸乙酯中的一种或几种的混合;Preferably, the second solvent is a mixture of one or more of dichloromethane, N,N-dimethylformamide and ethyl acetate;
优选的,所述第二缩合剂为HATU、HBTU和BOP中的一种或几种的组合;Preferably, the second condensing agent is one or a combination of HATU, HBTU and BOP;
优选的,所述第二催化剂为HOBt。Preferably, the second catalyst is HOBt.
本发明的在一目的是提供上述双自由基化合物及其盐在动态核极化中的应用。One object of the present invention is to provide the application of the above-mentioned diradical compounds and their salts in dynamic nuclear polarization.
本发明具有的优点和积极效果是:该化合物通过连接链将氮氧自由基与三芳基甲基自由基相连,形成了同时具有氮氧自由基和三芳基甲基自由基的双自由基极化剂。该双自由基极化剂的优势是:氮氧自由基-三芳基甲基自由基型双自由基的频率匹配性优于双氮氧自由基,CE效率更高;该氮氧自由基-三芳基甲基自由基型双自由基在魔角旋转的条件下不存在去极化效应,使其高场DNP增强效果优于双氮氧自由基;氮氧自由基-三芳基甲基自由基型双自由基具有的较强的交换相互作用明显区别于氮氧双自由基,且由于高场DNP偶极相互作用的影响非常小,起主导作用的是交换相互作用,因此,较强的交换相互作用也使该化合物具有相比于氮氧双自由基化合物更高的高场DNP增强倍数;三芳基甲基自由基具有良好的水溶性,且可修饰位点丰富,可用于不同用途的功能衍生化;本发明中对R1、R2、R3、R4、R5、R6基团的修饰可适度提高交换相互作用、提高双自由基的弛豫时间和双自由基的水溶性,从而提高极化剂的DNP性质。The invention has the advantages and positive effects that: the compound connects the nitroxide radical with the triarylmethyl radical through the linking chain, forming a double radical polarization with both nitroxide radical and triarylmethyl radical agent. The advantages of the double radical polarizer are: the frequency matching of nitroxide radical-triarylmethyl radical type double radical is better than that of nitroxide radical, and the CE efficiency is higher; Under the condition of magic angle rotation, the nitroxyl radical type diradical has no depolarization effect, which makes its high-field DNP enhancement effect better than that of dinitroxide radical; nitroxyl radical-triarylmethyl radical type The strong exchange interaction of diradicals is obviously different from that of nitroxide diradicals, and because the influence of high-field DNP dipole interaction is very small, the dominant role is the exchange interaction. Therefore, the strong exchange interaction The effect also makes the compound have a higher high-field DNP enhancement multiple than the nitroxide biradical compound; the triarylmethyl radical has good water solubility, and is rich in modifiable sites, which can be used for functional derivation for different purposes. The modification of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 groups in the present invention can moderately improve the exchange interaction, improve the relaxation time of diradicals and the water solubility of diradicals, Thereby enhancing the DNP properties of the polarizer.
附图说明Description of drawings
图1是本发明实施例一中化合物1的高分辨质谱图。Fig. 1 is a high-resolution mass spectrum of
图2是本发明实施例二中化合物2的高分辨质谱图。Fig. 2 is a high-resolution mass spectrum of
图3是本发明实施例三中化合物3的高分辨质谱图。3 is a high-resolution mass spectrum of
图4是本发明实施例四中化合物4的高分辨质谱图。4 is a high-resolution mass spectrum of
图5是本发明实施例五中化合物5的高分辨质谱图。Fig. 5 is a high-resolution mass spectrum of
图6是本发明实施例六中化合物6的高分辨质谱图。6 is a high-resolution mass spectrum of
图7是本发明实施例七中化合物7的高分辨质谱图。7 is a high-resolution mass spectrum of compound 7 in Example 7 of the present invention.
图8是本发明实施例八中化合物8的高分辨质谱图。FIG. 8 is a high-resolution mass spectrum of compound 8 in Example 8 of the present invention.
图9是本发明实施例九中化合物9的高分辨质谱图。9 is a high-resolution mass spectrum of compound 9 in Example 9 of the present invention.
具体实施方式Detailed ways
下面结合实施例对本发明的具体实施方式做进一步介绍:The specific embodiments of the present invention are further introduced below in conjunction with the examples:
实施例一Example 1
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
化合物1的制备步骤如下式11:The preparation steps of
一、化合物A4的制备:1. Preparation of compound A4:
二、化合物1的制备:Second, the preparation of compound 1:
1.将化合物A1(1-1.5eq)和HOBt(2-5eq)用重蒸的DCM溶解,搅拌,加入DIPEA(3-10eq),BOP(0.9-1.5eq)先用重蒸DCM溶解,再加入反应液,活化0.5-2h,然后将化合物A2(0.9-2eq)溶于重蒸DCM,加入反应液,室温反应0.5-18h。处理:用DCM、水萃取,依次用柠檬酸,饱和碳酸钠溶液,饱和食盐水洗,无水硫酸钠干燥,过滤,减压浓缩,用正相硅胶柱分离,流动相为:乙酸乙酯:石油醚=1:4–2:1,得产物A3,产率为65-95%。1. Dissolve compound A1 (1-1.5eq) and HOBt (2-5eq) in redistilled DCM, stir, add DIPEA (3-10eq), BOP (0.9-1.5eq) first dissolve in redistilled DCM, then The reaction solution was added, activated for 0.5-2h, then compound A2 (0.9-2eq) was dissolved in redistilled DCM, added to the reaction solution, and reacted at room temperature for 0.5-18h. Treatment: extracted with DCM, water, washed with citric acid, saturated sodium carbonate solution, saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by normal phase silica gel column, mobile phase: ethyl acetate: petroleum Ether=1:4-2:1 to give product A3 in 65-95% yield.
2.采用三氟乙酸或甲酸切除化合物A3的Boc基团,条件:A3在纯酸或酸的二氯甲烷溶液(酸的比率为1:5至2:1)中常温搅拌0.5-8h;然后真空去除溶剂和酸后,通过碱化、萃取操作得到切除Boc的A3。2. Use trifluoroacetic acid or formic acid to excise the Boc group of compound A3, condition: A3 is stirred at room temperature for 0.5-8h in pure acid or acid in dichloromethane solution (acid ratio is 1:5 to 2:1); then After the solvent and acid were removed in vacuo, A3 with Boc excised was obtained by alkalization and extraction.
3.将A4(0.9-1.5eq)溶于DMF中并加入DIPEA(3-20eq),将HBTU(0.9-2eq)溶于DMF中,滴加到反应液中,活化0.5-2h,将切除Boc的A3溶于适量DMF中,慢慢滴加(5-60min)到反应液中,4-24h后反应完全。加入稀盐酸,用乙酸乙酯、水萃取,合并有机层,减压浓缩,NaOH溶液中和成盐,通过反相硅胶柱层析进行分离。产率为15-50%左右。3. Dissolve A4 (0.9-1.5eq) in DMF and add DIPEA (3-20eq), dissolve HBTU (0.9-2eq) in DMF, add dropwise to the reaction solution, activate for 0.5-2h, and remove Boc The A3 was dissolved in an appropriate amount of DMF, slowly added dropwise (5-60min) to the reaction solution, and the reaction was complete after 4-24h. Dilute hydrochloric acid was added, extracted with ethyl acetate and water, the organic layers were combined, concentrated under reduced pressure, neutralized with NaOH solution to form a salt, and separated by reverse-phase silica gel column chromatography. Yields are around 15-50%.
本实施例中,化合物A1为市售可购买。化合物A2市售可购买。In this embodiment, compound A1 is Commercially available. Compound A2 Commercially available.
如图1为本实施例中化合物1的高分辨质谱数据。Figure 1 shows the high-resolution mass spectrometry data of
三、化合物1的DNP增强效果实验3. DNP-enhancing effect experiment of
DNP实验是将双自由基极化剂溶解到DNP juice(甘油/水/重水60%/30%/10%)中配成浓度为10mM的溶液,底物为13C-15N脯氨酸。DNP实验是在800MHz Bruker BioSpin527GHz固体核磁波谱仪上进行的,验温度为100K。The DNP experiment is to dissolve the double radical polarizer into DNP juice (glycerol/water/heavy water 60%/30%/10%) to prepare a solution with a concentration of 10mM, and the substrate is 13 C- 15 N proline. DNP experiments were carried out on an 800MHz Bruker BioSpin527GHz solid-state NMR spectrometer at a temperature of 100K.
化合物1的DNP增强倍数为57。The DNP enhancement fold of
实施例二
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
一、化合物2的制备步骤与实施例一中的方法相同。1. The preparation steps of
本实施例中,化合物A1为市售可购买。In this embodiment, compound A1 is Commercially available.
如图2为本实施例中化合物2的高分辨质谱数据Figure 2 shows the high-resolution mass spectrometry data of
二、化合物2的DNP增强效果实验2. DNP-enhancing effect experiment of
DNP增强性能测试的实验方法与化合物1测试实验方法相同。The experimental method of DNP enhancement performance test is the same as that of
化合物2的DNP增强倍数为76。与化合物1相比,DNP增强倍数有了33%的增幅,提升效果显著。The DNP enhancement fold of
实施例三
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
化合物3的制备步骤如下式13:The preparation step of
一、化合物3的制备:1. Preparation of compound 3:
将二甘醇胺(0.5-2eq),咪唑(2-5eq),DMAP(0.05-0.5eq),叔丁基二甲基氯硅烷(0.5-2eq)置于反应瓶中,氩气保护,冰浴,加入无水DCM,零度搅拌半小时后移置室温搅拌2-18小时反应完全。反应后处理:用饱和食盐水洗,蒸干即得纯净产物6,为无色透明油状物,产率达75-95%。Diethylene glycolamine (0.5-2eq), imidazole (2-5eq), DMAP (0.05-0.5eq), tert-butyldimethylsilyl chloride (0.5-2eq) were placed in a reaction flask, argon protection, ice bath, adding anhydrous DCM, stirring at zero temperature for half an hour, then transferring to room temperature and stirring for 2-18 hours to complete the reaction. Post-reaction treatment: washing with saturated brine, and evaporating to dryness to obtain
将上步所得产物(0.9-2eq)和氮氧自由基(1eq)溶于无水THF中,氩气保护,室温搅拌2小时,然后分批加入三乙酰氧基硼氢化钠(1.5eq),室温搅拌16小时,反应完全。减压浓缩,用DCM萃取,用饱和碳酸氢钠和饱和食盐水洗,无水硫酸钠干燥,过滤,减压浓缩,采用正相硅胶柱层析进行分离。流动相为0-5%甲醇/二氯甲烷。产率55-75%。The product obtained in the previous step (0.9-2eq) and nitroxide radical (1eq) were dissolved in anhydrous THF, under argon protection, stirred at room temperature for 2 hours, and then added in batches of sodium triacetoxyborohydride (1.5eq), After stirring at room temperature for 16 hours, the reaction was complete. It was concentrated under reduced pressure, extracted with DCM, washed with saturated sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by normal phase silica gel column chromatography. The mobile phase was 0-5% methanol/dichloromethane. Yield 55-75%.
剩余步骤同上,另外,在脱Boc时,TBS也会完全脱掉。The remaining steps are the same as above. In addition, when removing Boc, TBS will also be completely removed.
原始原料为市售可以购买到的。The raw materials are commercially available.
如图3为本实施例中化合物3的高分辨质谱数据。Figure 3 shows the high-resolution mass spectrometry data of
二、化合物3的DNP增强效果实验2. Experiment of DNP-enhancing effect of
DNP增强性能测试的实验方法与化合物1相同。The experimental method of DNP enhancement performance test is the same as
化合物3的DNP增强倍数为44,虽然增强倍数不及化合物1,但其在削弱了分子间的氢键相互作用的同时,依旧保持了可观的DNP增强倍数,故化合物3在某些特定环境中的性能显著优于化合物1,例如在某些脂溶性蛋白质或膜蛋白样品测试中,化合物3的水溶性和分散性优于化合物1,可体现更好的性能。The DNP enhancement factor of
实施例四
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
一、化合物4的制备:1. Preparation of compound 4:
化合物4的制备方法与化合物3相同。The preparation method of
如图4为本实施例中化合物4的高分辨质谱数据。Figure 4 shows the high-resolution mass spectrometry data of
二、化合物4的DNP增强效果实验2. Experiment of DNP-enhancing effect of
DNP增强性能测试的实验方法与化合物1相同。The experimental method of DNP enhancement performance test is the same as
化合物4的DNP增强倍数为20,虽然增强倍数不及化合物1,但其在削弱了分子间的氢键相互作用的同时,依旧保持了可观的DNP增强倍数,故化合物4在某些特定环境中的性能显著优于化合物1,例如在某些脂溶性蛋白质或膜蛋白样品测试中,化合物4的水溶性和分散性优于化合物1,可体现更好的性能。The DNP enhancement factor of
实施例五
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
化合物5的制备步骤如下式14:The preparation procedure of
一、化合物5的制备:1. Preparation of compound 5:
将2,2,6,6-四甲基-4-哌啶酮(0.5-2eq),4-羟基环己酮(3-6eq)和NH4Cl(3-6e q)溶于DMSO中,并在40-60℃加热搅拌5-12小时。加稀盐酸酸化,用石油醚萃取,用饱和碳酸钠溶液调pH=9,减压浓缩得到粗产物,通过正相硅胶柱层析进行纯化,流动相为1-5%MeOH/DCM,得到产物为白色固体,产率为10-30%。2,2,6,6-Tetramethyl-4-piperidinone (0.5-2eq), 4-hydroxycyclohexanone (3-6eq) and NH4Cl (3-6eq) were dissolved in DMSO, And heated and stirred at 40-60 ° C for 5-12 hours. Add dilute hydrochloric acid to acidify, extract with petroleum ether, adjust pH=9 with saturated sodium carbonate solution, concentrate under reduced pressure to obtain the crude product, which is purified by normal phase silica gel column chromatography, the mobile phase is 1-5% MeOH/DCM, to obtain the product As a white solid, the yield is 10-30%.
向上步产物(0.5-2eq)和Na2WO4·2H2O(0.3-1eq)的水溶液中在冰浴条件下加入30%H2O2(5-10eq),室温搅拌过夜。减压浓缩得到粗产物,通过硅胶柱层析进行纯化,流动相为1-3%MeOH/CH2Cl2,产物为红色油状物,产率为70-85%。30% H 2 O 2 (5-10 eq) was added to an aqueous solution of the product from the previous step (0.5-2 eq) and Na 2 WO 4 ·2H 2 O (0.3-1 eq) in an ice bath, and stirred at room temperature overnight. Concentration under reduced pressure gave the crude product, which was purified by silica gel column chromatography, the mobile phase was 1-3% MeOH/CH 2 Cl 2 , and the product was a red oil with a yield of 70-85%.
后续反应和化合物3相同。The subsequent reaction is the same as
原料为市售可购买到的。Raw materials are commercially available.
如图5为本实施例中化合物5的高分辨质谱数据。Figure 5 shows the high-resolution mass spectrometry data of
二、化合物5的DNP增强效果实验2. Experiment of DNP-enhancing effect of
化合物5的DNP增强倍数为72倍,相较化合物1有了26%的增幅,提升效果明显。The DNP enhancement multiple of
实施例六
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
化合物6的制备步骤如下式15:The preparation procedure of
一、化合物6的制备:1. Preparation of compound 6:
向2,2,6,6-四甲基-4-哌啶酮(0.5-2eq)的甲苯(5-15mL)溶液中加入多聚甲醛(1-2eq),所得溶液在100-120℃下加热搅拌并回流0.5-2小时,然后滴加甲酸(0.5-2eq),回流3-8小时后,将反应液冷却至室温。用乙酸乙酯萃取,依次用1N NaOH和饱和食盐水洗涤。有机层经无水硫酸钠干燥,过滤,减压浓缩,得到粗产物,通过正相硅胶柱层析进行纯化,流动相为乙酸乙酯:石油醚=1:3,得到产物,产率为40-60%。To a solution of 2,2,6,6-tetramethyl-4-piperidinone (0.5-2eq) in toluene (5-15mL) was added paraformaldehyde (1-2eq), the resulting solution was heated at 100-120°C Heating and stirring and refluxing for 0.5-2 hours, then dropwise addition of formic acid (0.5-2eq), after refluxing for 3-8 hours, the reaction solution was cooled to room temperature. It was extracted with ethyl acetate, washed with 1N NaOH and saturated brine in this order. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by normal phase silica gel column chromatography, and the mobile phase was ethyl acetate: petroleum ether=1:3 to obtain the product in a yield of 40 -60%.
将1,2,2,6,6-五甲基-4-哌啶酮(0.5-2eq),4-羟基环己酮(3-6eq)和NH4Cl(3-6eq)溶于DMSO中,并在50-70℃加热搅拌6-12小时。用稀盐酸酸化,用石油醚萃取,用饱和碳酸钠溶液调pH=9,减压浓缩得到粗产物,用正相硅胶柱层析进行纯化,流动相为5%MeOH/DCM,得到产物为白色固体,产率为12%。Dissolve 1,2,2,6,6-pentamethyl-4-piperidinone (0.5-2eq), 4-hydroxycyclohexanone (3-6eq) and NH4Cl (3-6eq) in DMSO , and heated and stirred at 50-70 ° C for 6-12 hours. Acidify with dilute hydrochloric acid, extract with petroleum ether, adjust pH=9 with saturated sodium carbonate solution, concentrate under reduced pressure to obtain crude product, which is purified by normal phase silica gel column chromatography, mobile phase is 5% MeOH/DCM, and the product is white Solid, 12% yield.
向上步产物(0.5-2eq)和Na2WO4·2H2O(0.3-1eq)的水溶液中在冰浴条件下加入30%H2O2(5-12eq),室温搅拌过夜。减压浓缩得到粗产物,通过硅胶柱层析进行纯化,流动相为1-3%MeOH/CH2Cl2,产物为红色油状物,产率为75-90%。30% H 2 O 2 (5-12 eq) was added to an aqueous solution of the product from the previous step (0.5-2 eq) and Na 2 WO 4 ·2H 2 O (0.3-1 eq) in an ice bath, and stirred at room temperature overnight. Concentration under reduced pressure gave the crude product, which was purified by silica gel column chromatography, the mobile phase was 1-3% MeOH/CH 2 Cl 2 , and the product was a red oil with a yield of 75-90%.
后续反应和化合物3相同。The subsequent reaction is the same as
原料均为市售可购买到的。The raw materials are all commercially available.
如图6为本实施例中化合物6的高分辨质谱数据。FIG. 6 is the high-resolution mass spectrometry data of
二、化合物6的DNP增强效果实验2. Experiment of DNP-enhancing effect of
DNP增强性能测试的实验方法与化合物1相同。The experimental method of DNP enhancement performance test is the same as
化合物6的DNP增强倍数为95。The DNP enhancement fold of
实施例七Embodiment 7
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
一、化合物7的制备:1. Preparation of compound 7:
化合物7的制备方法与化合物1相同。The preparation method of compound 7 is the same as that of
本实施例中,化合物A1为市售可购买。In this embodiment, compound A1 is Commercially available.
如图7为本实施例中化合物7的高分辨质谱数据。Figure 7 shows the high-resolution mass spectrometry data of compound 7 in this example.
二、化合物7的DNP增强效果实验2. Experiment of DNP-enhancing effect of compound 7
DNP增强性能测试的实验方法与化合物1相同。The experimental method of DNP enhancement performance test is the same as
化合物4的DNP增强倍数为40。The DNP enhancement factor of
实施例八Embodiment 8
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
一、化合物8的制备:1. Preparation of compound 8:
化合物8的制备方法与化合物1相同。The preparation method of compound 8 is the same as that of
本实施例中,化合物A1为市售可购买。In this embodiment, compound A1 is Commercially available.
如图8为本实施例中化合物8的高分辨质谱数据。FIG. 8 is the high-resolution mass spectrometry data of compound 8 in this example.
二、化合物8的DNP增强效果实验2. Experiment of DNP-enhancing effect of compound 8
DNP增强性能测试的实验方法与化合物1相同。The experimental method of DNP enhancement performance test is the same as
化合物8的DNP增强倍数为30。The DNP enhancement factor of compound 8 was 30.
实施例九Embodiment 9
本实施例所述的一种三芳基甲基自由基与氮氧自由基组成的双自由基化合物及其盐,结构式如下式:The biradical compound and its salt that a kind of triarylmethyl radical and nitroxide radical described in this embodiment are formed, the structural formula is as follows:
一、化合物9的制备:1. Preparation of compound 9:
化合物9的制备方法与化合物1相同。The preparation method of compound 9 is the same as that of
如图9为本实施例中化合物9的高分辨质谱数据。Figure 9 shows the high-resolution mass spectrometry data of compound 9 in this example.
二、化合物9的DNP增强效果实验2. Experiment of DNP-enhancing effect of compound 9
DNP增强性能测试的实验方法与化合物1相同。The experimental method of DNP enhancement performance test is the same as
化合物8的DNP增强倍数为43。The DNP enhancement fold of compound 8 was 43.
以上对本发明的几个实施例进行了详细说明,但所述内容仅为本发明的较佳实施例,不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等,均应仍归属于本发明的专利涵盖范围之内。Several embodiments of the present invention have been described in detail above, but the above contents are only preferred embodiments of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made according to the scope of the application of the present invention should still belong to the scope of the patent of the present invention.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810824031.7A CN108794510B (en) | 2018-07-25 | 2018-07-25 | A double-radical compound composed of triarylmethyl radical and nitroxide radical and salt thereof, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810824031.7A CN108794510B (en) | 2018-07-25 | 2018-07-25 | A double-radical compound composed of triarylmethyl radical and nitroxide radical and salt thereof, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108794510A CN108794510A (en) | 2018-11-13 |
CN108794510B true CN108794510B (en) | 2021-08-06 |
Family
ID=64078136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810824031.7A Active CN108794510B (en) | 2018-07-25 | 2018-07-25 | A double-radical compound composed of triarylmethyl radical and nitroxide radical and salt thereof, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108794510B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4148058A1 (en) * | 2021-09-13 | 2023-03-15 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Trityl-nitroxide multiradicals as polarizing agents for dynamic nuclear polarization |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101027310A (en) * | 2004-07-30 | 2007-08-29 | 通用电气医疗集团股份有限公司 | Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process |
WO2008026937A1 (en) * | 2006-08-30 | 2008-03-06 | Ge Healthcare As | Method of dynamic nuclear polarisation (dnp) and compounds and compositions for use in the method |
-
2018
- 2018-07-25 CN CN201810824031.7A patent/CN108794510B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101027310A (en) * | 2004-07-30 | 2007-08-29 | 通用电气医疗集团股份有限公司 | Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process |
WO2008026937A1 (en) * | 2006-08-30 | 2008-03-06 | Ge Healthcare As | Method of dynamic nuclear polarisation (dnp) and compounds and compositions for use in the method |
Non-Patent Citations (5)
Title |
---|
Diastereoisomers of L-proline-linked tritylnitroxide biradicals: synthesis and effect of chiral configurations on exchange interactions;Weixiang Zhai et al.;《Chem. Sci.》;20180405;第9卷;4381-4391 * |
Efficient Dynamic Nuclear Polarization at 800 MHz/527 GHz with Trityl-Nitroxide Biradicals;Guinevere Mathies et al.;《Angew.Chem.Int.Ed.》;20151231;第54卷;11770-11774 * |
Structural Factors Controlling the Spin−Spin Exchange Coupling:EPR Spectroscopic Studies of Highly Asymmetric Trityl−Nitroxide Biradicals;Yangping Liu et al.;《J. Am. Chem. Soc.》;20130115;第135卷;2350-2356 * |
Supramolecular host–guest interaction of tritylnitroxide biradicals with cyclodextrins: modulation of spin–spin interaction and redox sensitivity;Xiaoli Tan et al.;《Org. Biomol. Chem.》;20151218;第14卷;1694-1701 * |
Yangping Liu et al..Structural Factors Controlling the Spin−Spin Exchange Coupling:EPR Spectroscopic Studies of Highly Asymmetric Trityl−Nitroxide Biradicals.《J. Am. Chem. Soc.》.2013,第135卷2350-2356. * |
Also Published As
Publication number | Publication date |
---|---|
CN108794510A (en) | 2018-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103641890B (en) | The synthetic method of a kind of Ka Feizuo meter | |
CN109400501B (en) | Functionalized pillar aromatic derivatives and preparation method thereof | |
WO2020155879A1 (en) | Compound containing benzyl structure and use thereof | |
CN108794510B (en) | A double-radical compound composed of triarylmethyl radical and nitroxide radical and salt thereof, preparation method and application thereof | |
CN103864898A (en) | Preparation method of kyprolis | |
WO2020186840A1 (en) | Compound containing fluorene ring structure and application thereof | |
CN109134875B (en) | Preparation of Chiral Covalent Organic Framework Materials Using L-Menthol as Chiral Source | |
CN104974156B (en) | 1, 5, 9-triazanaphthalene coronene compound and synthetic method thereof | |
CN109020856A (en) | Thiocarbamide polyether-bridged chiral molecular tweezer and its preparation and application | |
CN108794520B (en) | Synthesis method of boric acid citrate compounds including ixazomib | |
CN102513023B (en) | Trimeric surfactant and synthetic method thereof | |
CN106588924A (en) | Perfluoroalkyl-modified perylene imide and its preparation method | |
WO2023092715A1 (en) | Alanine aggregation-induced emission fluorescent probe, and synthesis method therefor and use thereof | |
Zhu et al. | Hydrogen bonding-mediated self-assembly of anthranilamide-based homodimers through preorganization of the amido and ureido binding sites | |
CN102924463A (en) | Multi-anchor self-assembled porphyrin and synthetic method thereof | |
CN111943879A (en) | A kind of (3S, 4R) 3-amino-4 (methoxymethyl) pyrrolidine-1-carboxylic acid tert-butyl ester and its synthesis method | |
JP4934055B2 (en) | Method for producing isochroman and derivatives thereof | |
CN111826153B (en) | Temperature-sensitive amphiphilic dendritic macromolecule based on tetraphenylethylene and preparation method thereof | |
CN111393426A (en) | Rivaroxaban thiophene carboxylate impurity reference substance and preparation method thereof | |
CN105777620B (en) | A kind of Fluorenone pyridine green fluorescent material | |
CN114105961B (en) | Preparation method of an IDO1 inhibitor (LY-3381916) | |
CN110437158A (en) | A kind of preparation and application of anthryl hydrogen bond molecular folding material | |
Dodziuk et al. | 1: 3 Complex between b-Cyclodextrin and Dendrimer with Three Branches Involving Four Glycine and One Adamantyl Group | |
CN106748837A (en) | Dimethoxy-benzophenone compound of 5,5 ' diaryl, 3,3 ' diaminourea 4,4 ' and preparation method thereof | |
CN105753873A (en) | Preparation method of octahydroxy Schiff base metal phthalocyanine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
OL01 | Intention to license declared | ||
OL01 | Intention to license declared |